Howard Liebman, MD

Professor of Medicine and Pathology

Donald I. Feinstein, MD, Chair in Hematology

Image of Howard Liebman, MD
Is this your profile? Click to edit

Overview

Dr. Howard Liebman, Professor of Medicine and Pathology is the author or co-author of over 170 peer reviewed publications, review articles and chapters. He has presented over two hundred lectures across the United States, South America, Europe. Korea and Japan. He has served as the former Chair of the Massachusetts Governor’s Task Force subcommittee on experimental therapies and clinical trials for AIDS. He is a medical advisor for the Platelet Disorder Support Association and a member of the Cancer and Thrombosis Guidelines Committee of the American Society of Clinical Oncology. He has served on several grant review committees for the National Institute of Health. He presently holds the Donald I Feinstein Endowed Chair of Hematology.

In addition to his academic responsibilities, Dr. Liebman is an attending staff member of the LAC+USC Medical Center, the USC/Norris Comprehensive Cancer Center and the Keck Hospital of USC. Dr. Liebman also is on the forefront of research in thrombotic and hemorrhagic disorders. His lab is currently studying the genetic risk factors responsible for thrombotic diseases including venous thrombosis, pulmonary embolism, and arterial thrombosis. Dr. Liebman is also internationally known for his work in the relationships between venous thrombotic disease and underlying malignancy. He has been and is the principal investigator on several clinical trials in the management of immune thrombocytopenia (ITP). His research group has made important discoveries on the role of infectious agents in the development of immune thrombocytopenia and secondary ITP.

Awards

  • Fellow, American College of Physicians

Education and Training

  • Keck School of Medicine — MD — Medical School, Doctor of Medicine
  • LAC + USC Medical Center — Internship, Internal Medicine
  • LAC + USC Medical Center — Residency, Internal Medicine
  • LAC + USC Medical Center — Fellowship, Hematology
  • Tufts-New England Medical Center — Fellowship in Immunochemistry and coagulation chemistry

Research Funding

  • ROLE OF METAL IONS IN THE FUNCTION OF HUMAN FACTOR IX
    NIH · R29HL039665 · Feb 15, 1988 – Mar 1, 1994 · Role: Principal Investigator

Publications

  • A Qualitative Study on Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia. Patient. 2026 01; 19(1):69-82.. View in PubMed
  • Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. Blood. 2025 Jun 12; 145(24):2914-2926.. View in PubMed
  • Thrombosis in immune thrombocytopenia. Clin Adv Hematol Oncol. 2025 Mar-Apr; 23(2):87-89.. View in PubMed
  • Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit. Thromb Haemost. 2025 Sep; 125(9):923-932.. View in PubMed
  • Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study. Ther Adv Hematol. 2023; 14:20406207231205431.. View in PubMed
  • Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP. Br J Haematol. 2023 10; 203(1):96-100.. View in PubMed
  • Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia. Res Pract Thromb Haemost. 2023 Mar; 7(3):100134.. View in PubMed
  • The unique diagnostic and management challenge of a patient with concomitant anti-interferon-gamma autoantibody associated immunodeficiency syndrome, IgG4-related disease, and treatment refractory, disseminated mycobacterium avium complex infection. Allergy Asthma Clin Immunol. 2022 Sep 09; 18(1):82.. View in PubMed
  • SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood. 2022 03 10; 139(10):1564-1574.. View in PubMed
  • Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol. 2022 05; 197(3):359-366.. View in PubMed